322-79-2 Usage
Description
2-Acetoxy-4-trifluoromethylbenzoic acid is a chemical compound characterized by its white to off-white solid appearance. It is structurally related to salicylates and is an analog of Aspirin, which means it shares similar properties and functions.
Uses
Used in Pharmaceutical Industry:
2-Acetoxy-4-trifluoromethylbenzoic acid is used as an antithrombotic agent for its ability to inhibit platelet aggregation. This property makes it a valuable compound in the development of medications aimed at preventing blood clot formation, which can lead to conditions such as stroke and heart attack.
Used in Cyclooxygenase Inhibition:
In the pharmaceutical industry, 2-Acetoxy-4-trifluoromethylbenzoic acid is also used as a cyclooxygenase inhibitor. This application is significant because cyclooxygenase enzymes play a role in the production of prostaglandins, which are involved in inflammation and pain. By inhibiting these enzymes, the compound can potentially be used in the development of anti-inflammatory and pain-relieving medications.
Used in Alzheimer's Disease Treatment:
2-Acetoxy-4-trifluoromethylbenzoic acid has been studied for its potential use in treating vascular dementia (VaD) and amnestic mild cognitive impairment (MCI). In a 12-month open-label trial, patients with VaD showed fewer declines in cognitive scores when treated with the compound compared to untreated subjects. Additionally, a study involving patients with amnestic MCI found that treatment with the compound was associated with a significantly lower rate of conversion to dementia. This suggests that 2-Acetoxy-4-trifluoromethylbenzoic acid could be a promising therapeutic option for patients with cognitive impairments and dementia-related conditions.
Pharmacological Study
Triflusal is an antiplatelet agent structurally related to the
salicylates, but it is not derived from ASA. Triflusal and its
metabolite (3-hydroxy-4-triuoro-methylbenzoic acid or
HTB) produce specific inhibition of platelet arachidonic acid
metabolism (McNeely and Goa, 1998). A single 12-month
open-label trial of tritriflusal in 73 VaD patients (López-Pousa
et al., 1997) showed fewer declines in MMSE scores in
the active group compared with untreated subjects. More
recently, triusal was used in patients with amnesic MCI;
257 patients were randomized to receive 900 mg of triflusal
or placebo for 18 months. Triflusal therapy was associated
with a signi cantly lower rate of conversion to dementia
(Gómez-Isla et al., 2008).
Mechanism of action
2-hydroxy-4-trifluoromethylbenzoic acid (HTB), the deacetylated
metabolite of triflusal, retains significant antiplatelet activity. Triflusal is rapidly absorbed and
metabolized. The area under the concentration–time curve for triflusal is 20.26 mg/L/hour after a
900-mg dose, whereas that for HTB is 42.27 mg/L/hour. Much of the pharmacokinetic data for
triflusal activity is associated with HTB. The inhibition of COX, as measured by reduced production
of thromboxane B2, is 25% after 2 hours and 85% after 7 days with triflusal, whereas the effects of
aspirin on thromboxane B2 is more than 90% reduction after 2 hours and is maintained at this level
after 7 days. It would appear that the presence of a 4-trifluoromethyl group also greatly enhances triflusal's ability to inhibit the activation of nuclear factor κB, which in turn regulates the
expression of the mRNA of vascular
cell adhesion molecule-1 needed for platelet aggregation. In addition, triflusal increases nitric
oxide synthesis in neutrophils, which results in an increased vasodilatory potential. Finally, an
additional site of action for triflusal/HTB is the inhibition of cAMP phosphodiesterase, leading to
increased levels of cAMP. Elevated cAMP levels decrease platelet aggregation through decreased
mobilization of calcium. Aspirin and salicylic acid do not significantly increase cAMP levels.
Clinical Use
Triflusal (2-acetoxy-4-trifluoromethyl benzoic acid) is an antiplatelet drug that despite its structural
similarity to aspirin exhibits quite different pharmacological and pharmacokinetic
properties.
Check Digit Verification of cas no
The CAS Registry Mumber 322-79-2 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,2 and 2 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 322-79:
(5*3)+(4*2)+(3*2)+(2*7)+(1*9)=52
52 % 10 = 2
So 322-79-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)
